Press Releases - 2009

12/14/2009
Columbia Laboratories Announces Leadership Changes
Frank Condella appointed as interim chief executive officer; Robert Mills assumes the role of president and chief operating officer

12/10/2009
Columbia Laboratories Recieves NASDAQ Notice of Non-Compliance with Minimum Bid Price Rule
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it received a notice on December 9, 2009 from the NASDAQ Stock Market indicating that the Company no longer meets the minimum bid price requirement for continued listing on the NASDAQ Global Market as set forth in Marketplace Rule 5450(a)(1).

11/13/2009
Columbia Laboratories Comments on Stock Activity
Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock.

11/9/2009
“Crinone® 8% (progesterone vaginal gel) as Effective as Hormone Injections During IVF” is Medscape's “Top News” from the ASRM 65th Annual Meeting
Similar pregnancy rates and outcomes; time has come for new paradigm in progesterone treatment for luteal support, according to leading physician quoted by Medscape

11/5/2009
Columbia Laboratories Reports Third Quarter 2009 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and nine-month periods ended September 30, 2009.

10/28/2009
Columbia Laboratories Closes Registered Direct Common Stock and Warrant Offering
Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $11,772,000 in gross proceeds to the Company through the sale of 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering.

10/27/2009
Columbia Laboratories to Present the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer 20th Annual Healthcare Conference

10/23/2009
Columbia Laboratories Announces Registered Direct Common Stock Offeringq
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it has priced a transaction to raise up to approximately $11,772,000 through the sale of up to approximately 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering. The common stock and warrants will be sold in units, with each unit consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock.

10/22/2009
Columbia Laboratories to Discuss Third Quarter 2009 Financial Results on November 5, 2009 Conference Call
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on November 5, 2009 to discuss financial results of the third quarter ended September 30, 2009. Robert S. Mills, president and chief executive officer, and Lawrence Gyenes, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.

10/22/2009
Bleeding is Rare in IVF Patients Who Become Pregnant When Treated With a Combination of Vaginal Progesterone Gel and Estrogen
A prospective, multi-center study demonstrated that in IVF (in vitro fertilization) cycles supplemented with once-daily dosing of Crinone® vaginal progesterone gel and Estrace® oral estrogen, vaginal bleeding is rare in patients who become pregnant. Bleeding does occur in approximately one-quarter of patients who do not become pregnant.

10/21/2009
Crinone8% (progesterone gel) is Equally Effective and Significantly Better Tolerated Than Intramuscular Progesterone; Similar Pregnancy Rates and Outcomes Reported
Researchers from Brigham & Women’s Hospital in Boston presented data from the largest, prospective, randomized clinical study to date comparing any vaginal progesterone to intramuscular injections of progesterone (IM progesterone) for infertility treatment.

10/20/2009
Clinical Pregnancy Rates Comparable in Older Women Undergoing IVF-ET, Using Three Different Progesterone Preparations; Once Daily Vaginal Gel May Improve Compliance
A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

10/19/2009
Columbia Laboratories Enjoys Major Roles at the 65th Annual Meeting of the American Society of Reproductive Medicine
Columbia Laboratories, Inc. (Nasdaq: CBRX), is a platinum sponsor and exhibitor at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM), taking place in Atlanta, October 17-21. Two oral presentations and two posters are also being presented at the conference by leading U.S. clinicians.

9/2/2009
Columbia Laboratories to Present the Rodman & Renshaw Annual Global Investment Conference on September 10, 2009
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Rodman & Renshaw Annual Global Investment Conference.

8/11/2009
Columbia Laboratories Partners with Resolve: The National Infertility Association to Sponsor and Provide Web Content for Infertile Couples
In an ongoing partnership with RESOLVE: The National Infertility Association, Columbia Laboratories (Nasdaq: CBRX) announced today that it will sponsor and provide content on the organization’s website about the role of progesterone supplementation in assisted reproductive technology (ART) treatments. In addition, the sponsored article titled Progesterone and Pregnancy: A Vital Connection discusses the important role progesterone plays in pregnancy and the various methods of administration of the hormone.

8/6/2009
Columbia Laboratories Reports Second Quarter 2009 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the second quarter of 2009.

7/29/2009
Columbia Laboratories to Discuss Second Quarter 2009 Financial Results on August 6, 2009 Conference Call
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on August 6, 2009 to discuss financial results of the second quarter ended June 30, 2009. Robert S. Mills, president and chief executive officer, and Lawrence Gyenes, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.

7/23/2009
Columbia Laboratories and Pharmabio Agree to One Year Extension of Final Payment Under Striant® Financing Agreement
Columbia Laboratories, Inc. (Nasdaq: CBRX) has signed an agreement with PharmaBio Development, Inc., an affiliate of Quintiles Transnational Corp., under which Columbia can extend its final royalty payment on sales of STRIANT® (testosterone buccal system) from November 2010 to November 2011. The final payment is estimated at approximately $16.4 million.

7/22/2009
Columbia Laboratories to Address Strategic Issues
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Frank C. Condella, Jr., the most recent addition to the Company’s Board of Directors and a seasoned pharmaceutical executive, will be working closely with management and the Board over the next three months to advise on strategic issues.

7/15/2009
Lawrence Gyenes Appointed Chief Financial Officer of Columbia Laboratories
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced the appointment of Lawrence Gyenes to the position of Senior Vice President, Chief Financial Officer and Treasurer. Mr. Gyenes will direct and oversee the financial management, accounting, information services and investor relations activities of the Company, effective immediately.

5/7/2009
Columbia Laboratories Reports First Quarter 2009 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced financial results for the three-month period ended March 31, 2009.

4/30/2009
Columbia Laboratories to Discuss First Quarter 2009 Financial Results on May 7, 2009 Conference Call
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on May 7, 2009 to discuss financial results of the first quarter ended March 31, 2009. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.

3/11/2009
Frank C. Condella, Jr. Elected to Columbia Laboratories Board of Directors
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that as of March 10, its Board of Directors elected Frank C. Condella, Jr. as a director of the Company. Mr. Condella is a non-executive director of Skyepharma plc and Fulcrum Pharma plc.

3/10/2009
Columbia Laboratories to Present at the Cowen and Company 29th Annual Health Care Conference On Match 16, 2009
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Cowen and Company 29th Annual Health Care Conference.

3/5/2009
Columbia Laboratories Reports Fourth Quarter and Year-end 2008 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced results for the fourth quarter and fiscal year ended December 31, 2008.

1/29/2009
Data from Columbia Laboratories’ Study for the Prevention of Preterm Birth to be Presented at the Society for Maternal-Fetal Medicine (SMFM) 2009 Annual Meeting
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that the PREGNANT Study, Columbia’s ongoing study to prevent preterm birth in pregnant women with a short cervical length will be discussed at a scientific session of the SMFM Annual Meeting held in San Diego, California, January 26 - 31, 2009.

1/7/2009
Columbia Laboratories Raises $750,000 through Sale of Common Stock Numoda Corporation Purchases Shares
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it has raised $750,000 through the sale of 451,807 shares of its common stock at a price of $1.66 per share to Numoda Corporation, which provides improved trial-performance metrics solutions in enrollment, logistics, monitoring and financial efficiencies for life sciences companies.